Gefitinib (ZD1839)

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
08013
Phase II study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC
10012
An IDBBC single arm phase II trial evaluating the activity of Iressa (ZD 1839) in metastatic breast cancer patients pretreated with an antiestrogen and a nonsteroidal aromatase inhibitor (anastrozole or letrozole).
08021
A randomized phase III study of follow up with or without adjuvant Gefitinib (Iressa TM) following chemotherapy in patients with advanced Non-Small Cell Lung Cancer.
10021
An EORTC randomized, double blind, placebo controlled, Phase II multi-center trial of anastrozole (Arimidex) in combination with ZD1839 (Irissa(R)) or placebo in patients with advanced breast cancer.
62022
Phase 2 study of Iressa (ZD 1839) in locally advanced and/or metastatic synovial sarcoma expressing HER1/EGFRI.

Back to Protocol section